Shed vs Brello: Coaching, Compounded Options, Pricing
Quick verdict: Shed vs Brello
The primary difference in Shed vs Brello is that Shed pairs name-brand and compounded GLP-1 options with continuous coaching and a 2-minute approval assessment, while Brello’s public details were not verified on the captured landing page. Early verdict: choose Shed if you want integrated coaching and a platform that offers both name-brand and compounded GLP-1 options; choose Brello only after you confirm current pricing, eligibility, pharmacy and state availability because those details were not captured.
Explore Shed’s options and start the 2-minute assessment
Head-to-head: most distinctive differences
This comparison focuses on five supported differences between Shed and Brello: medication options, coaching and support, pricing transparency and starting price, approval process speed, and regulatory notes about compounded medications. All claims below follow the captured evidence.
1. Medication options: name-brand plus compounded vs unverified
Shed explicitly offers both FDA-approved name-brand GLP-1 medications and compounded alternatives on one platform. The evidence states that Shed lets patients choose between name-brand products and compounded semaglutide or tirzepatide injections. For Brello, the captured landing-page evidence did not publish or verify current medication details. The comparison here is direct: Shed documents dual options; Brello’s specifics were not verified in the captured material.
2. Coaching and ongoing support
Shed integrates continuous coaching into treatment, describing coaching as part of the program rather than an add-on. The source says Shed pairs medication with continuous coaching to support titration and lifestyle changes. The Brello capture contains no verified description of coaching or support, so a direct contrast is that Shed’s coaching feature is documented while Brello’s coaching and program details were not captured.
3. Pricing transparency and starting price
Shed lists starting rates for compounded injections in captured landing-page evidence: compounded semaglutide injections starting at $199/month and compounded tirzepatide injections starting at $299/month. Shed also advertises 10% off the first month for new patients. The detailed FAQ notes Shed does not publish standard pricing and issues personalized quotes after intake, but starting amounts for compounded options were shown. For Brello, pricing and related details were not verified on the captured page, and the source warns pricing and terms may change, so confirm current costs directly with Brello before enrolling.
4. Approval process and speed
Shed uses a 2-minute online assessment to check eligibility, followed by clinician review before any prescription is issued. The material specifically states a 2-minute approval assessment and that a licensed clinician determines whether treatment is appropriate. The Brello capture does not verify approval timing; the only confirmed note is that treatment is available only when a licensed clinician determines it is medically appropriate. That makes Shed the only provider in these captures with an advertised rapid screening step.
5. Regulatory notes and compounded medications
Both the Shed materials and the Brello capture include regulatory caveats: compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Shed’s content explicitly repeats that compounded medications are prepared by a licensed pharmacy based on a provider’s prescription and are not FDA-approved. The Brello capture similarly notes medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable.
Comparison table: Shed vs Brello
| Criteria | Shed | Brello |
|---|---|---|
| Medication options | Name-brand and compounded GLP-1 offered | Not verified on captured page |
| Coaching and support | Continuous coaching integrated into treatment | Not captured or verified |
| Starting price | Compounded semaglutide from $199/month; compounded tirzepatide from $299/month; 10% off first month | Not verified on captured page |
| Approval process | 2-minute online assessment followed by clinician review | Treatment subject to clinician review; timing not captured |
| Regulatory note | Compounded meds are not FDA-approved; prescription after clinician review | Medication-specific approval status must be confirmed; compounded meds not FDA-reviewed |
Practical takeaways
If you want documented dual medication options and integrated coaching from the outset, Shed is the only provider in the captured evidence that advertises both name-brand and compounded GLP-1 plus continuous coaching and a 2-minute assessment. If you prefer to confirm current pricing, eligibility, pharmacy, renewal terms and state availability before enrolling, the Brello capture warns those items may change and were not verified on the captured landing page.
See Shed’s membership and medication options
Shed vs Brello: final guidance
Choose Shed if you want a platform that documents both name-brand and compounded GLP-1 options, integrates continuous coaching into treatment, and offers a 2-minute eligibility assessment with compounded injections starting at $199/month. Choose Brello if you need to confirm current pricing, eligibility, pharmacy, state coverage and renewal terms directly with Brello before enrolling because those details were not verified in the captured material.
Confirm Brello pricing and eligibility
Start Shed’s 2-minute assessment now